CAI Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.…
Industry Peers
BiotechnologyKey Statistics
About Caris Life Sciences (NASDAQ: CAI)
›
Caris Life Sciences (NASDAQ: CAI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,846 employees.
The shares were at 23.04 USD on 13 November 2026, down 7.0% over 52 weeks. Its 52-week range is 14.19 USD to 36.50 USD: the price is 36.9% below the high and 62.4% above the low.
At a market capitalisation of 6.61B USD, it trades at 13.9 times trailing earnings and 79.2 times forward earnings. The median trailing P/E of its 14 largest Biotechnology peers is 35.0, a discount of 60% for CAI.
Caris Life Sciences reports return on equity of -11.8%, an operating margin of 13.4% and revenue up 27.0% year over year.
It holds more cash than debt, a net cash position of 304.36M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 34.23 USD is 48.6% above the current price. The next earnings report is expected on 25 February 2027.